Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104351 | 0.88 | FLT3 (0.56) | FLT3CHEK1SMYD3FGFR1FGFR2 | |
| SCHEMBL4095689 | 0.87 | FLT3 (0.49) | FLT3CHEK1SMYD3FGFR1FGFR2 | |
| SCHEMBL13849228 | 0.84 | CHEK1 (0.47) | FLT3CHEK1CDK2SMYD3 | |
| SCHEMBL13849237 | 0.84 | CHEK1 (0.47) | FLT3CHEK1CDK2SMYD3 | |
| SCHEMBL13849246 | 0.82 | FLT3 (0.49) | FLT3CHEK1SMYD3 | |
| SCHEMBL13849238 | 0.81 | FLT3 (0.48) | FLT3CHEK1CDK2SMYD3FGFR1 | |
| SCHEMBL13849193 | 0.81 | FLT3 (0.52) | FLT3CHEK1SMYD3 | |
| SCHEMBL13849212 | 0.81 | FLT3 (0.48) | FLT3CHEK1CDK2SMYD3 | |
| SCHEMBL4090783 | 0.81 | CHEK1 (0.56) | FLT3CHEK1SMYD3FGFR1 | |
| SCHEMBL13849241 | 0.80 | FLT3 (0.47) | FLT3CHEK1SMYD3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | FLT3 344/4885CHEK1 2/4885CDK4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.